LTRN - Lantern Pharma Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Dallas,
United States
Type: Equity
LTRN price evolution
LTRN
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $12.98 | $18.36 | $21.94 | $25.57 |
| Short term investments | $20.29 | $20 | $19.36 | $19.35 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $35.29 | $39.47 | $43.34 | $47.43 |
| Long term investments | ||||
| Property, plant & equipment | $0.26 | $0.24 | $0.28 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.3 | $0.26 | $0.31 | $0.35 |
| Total investments | $20.29 | $20 | $19.36 | $19.35 |
| Total assets | $35.59 | $39.73 | $43.65 | $47.77 |
| Current liabilities | ||||
| Accounts payable | $4.44 | $3.78 | $2.51 | $2.09 |
| Deferred revenue | ||||
| Short long term debt | $0.16 | $0.18 | $0.17 | $0.17 |
| Total current liabilities | $4.6 | $3.95 | $2.68 | $2.25 |
| Long term debt | $0.05 | $0.02 | $0.06 | $0.11 |
| Total noncurrent liabilities | $0.05 | $0.02 | $0.06 | $0.11 |
| Total debt | $0.22 | $0.19 | $0.23 | $0.27 |
| Total liabilities | $4.66 | $3.97 | $2.74 | $2.36 |
| Shareholders' equity | ||||
| Retained earnings | -$65.64 | -$60.69 | -$55.24 | -$51.06 |
| Other shareholder equity | -$0.01 | $0 | -$0.11 | -$0.14 |
| Total shareholder equity | $30.93 | $35.77 | $40.91 | $45.41 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21.94 | $37.2 | $52.52 | $19.23 |
| Short term investments | $19.36 | $17.99 | $19.2 | |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $43.34 | $58.72 | $72.72 | $20.24 |
| Long term investments | ||||
| Property, plant & equipment | $0.28 | $0.1 | $0.22 | $0.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.31 | $0.11 | $1.23 | $0.12 |
| Total investments | $19.36 | $17.99 | $19.2 | |
| Total assets | $43.65 | $58.84 | $73.95 | $20.36 |
| Current liabilities | ||||
| Accounts payable | $2.51 | $2.75 | $2.17 | $0.55 |
| Deferred revenue | ||||
| Short long term debt | $0.17 | $0.05 | $0.15 | |
| Total current liabilities | $2.68 | $2.8 | $2.33 | $0.55 |
| Long term debt | $0.06 | $0.05 | $0.11 | |
| Total noncurrent liabilities | $0.06 | $0.05 | $0.11 | |
| Total debt | $0.23 | $0.05 | $0.2 | $0.11 |
| Total liabilities | $2.74 | $2.8 | $2.38 | $0.66 |
| Shareholders' equity | ||||
| Retained earnings | -$55.24 | -$39.28 | -$25.02 | -$12.66 |
| Other shareholder equity | -$0.11 | -$0.37 | -$0.09 | |
| Total shareholder equity | $40.91 | $56.04 | $71.57 | $19.7 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $3.89 | $4.25 | $3.57 | |
| Selling, general & administrative | $1.52 | $1.48 | $1.3 | |
| Total operating expenses | $5.41 | $5.73 | $4.88 | |
| Operating income | -$5.41 | -$5.73 | -$4.88 | |
| Income from continuing operations | ||||
| EBIT | -$4.96 | -$5.44 | -$4.19 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$4.96 | -$5.44 | -$4.19 | |
| Income (for common shares) | -$4.96 | -$5.44 | -$4.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $11.89 | $8.6 | $7.57 | $2.24 |
| Selling, general & administrative | $5.98 | $5.83 | $5.02 | $3.66 |
| Total operating expenses | $17.88 | $14.43 | $12.59 | $5.91 |
| Operating income | -$17.88 | -$14.43 | -$12.59 | -$5.91 |
| Income from continuing operations | ||||
| EBIT | -$15.96 | -$14.26 | -$12.36 | -$5.91 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$15.96 | -$14.26 | -$12.36 | -$5.91 |
| Income (for common shares) | -$15.96 | -$14.26 | -$12.36 | -$5.91 |
| (in millions $) | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 | 30 Sep 2023 |
|---|---|---|---|---|
| Net income | -$4.96 | -$5.44 | -$4.19 | -$3.16 |
| Operating activities | ||||
| Depreciation | $0.05 | $0.05 | $0.04 | $0.04 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.13 | $0.13 | $0.15 | $0.19 |
| Total cash flows from operations | -$5.19 | -$3.07 | -$3.39 | -$3.61 |
| Investing activities | ||||
| Capital expenditures | -$0 | -$0 | -$0.01 | -$0 |
| Investments | -$0.2 | -$0.55 | $0.26 | $0.24 |
| Total cash flows from investing | -$0.2 | -$0.56 | $0.26 | $0.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | -$0.5 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.05 | -$0.5 | ||
| Effect of exchange rate | $0.01 | -$0.01 | -$0 | -$0.01 |
| Change in cash and equivalents | -$5.38 | -$3.58 | -$3.63 | -$3.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$15.96 | -$14.26 | -$12.36 | -$5.91 |
| Operating activities | ||||
| Depreciation | $0.17 | $0.15 | $0.1 | $0 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.07 | $1.19 | $0.96 | $1.19 |
| Total cash flows from operations | -$14.35 | -$12.77 | -$10.59 | -$5.65 |
| Investing activities | ||||
| Capital expenditures | -$0.02 | -$0.03 | -$0.02 | -$0.02 |
| Investments | -$0.91 | $0.21 | -$19.52 | |
| Total cash flows from investing | -$0.93 | $0.18 | -$19.53 | -$0.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.5 | -$2.48 | $68.06 | $26.3 |
| Net borrowings | $0.11 | |||
| Total cash flows from financing | -$0.5 | -$2.18 | $63.42 | $23.66 |
| Effect of exchange rate | -$0.03 | -$0.01 | $0 | |
| Change in cash and equivalents | -$15.81 | -$14.78 | $33.3 | $18 |
News
Fundamentals
| Market cap | $31.74M |
|---|---|
| Enterprise value | $18.98M |
| Shares outstanding | 10.76M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 1.03 |
| Book/Share | 2.88 |
| Cash/Share | 1.21 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.07 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 7.67 |
| Quick ratio | 7.67 |